Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Larazotide (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alba Therapeutics
- 11 Sep 2017 The protocol has been amended to include efficacy as the primary endpoint along with the safety. The trial focus changes to TU and AR.
- 12 Dec 2014 New trial record